Fermented Soymilk Spiked With GABA Could Become a Functional Beverage Worth Watching

Preliminary research published in Food Technology and Biotechnology describes a fermented soymilk product that may combine two sought-after properties: high concentrations of gamma-aminobutyric acid (GABA), a neurotransmitter associated with blood pressure regulation, anxiety reduction, and sleep, alongside viable probiotic bacteria. The study is early-stage, and the leap from a laboratory flask to a commercial refrigerator shelf involves hurdles the researchers themselves flag as unsolved. Still, the core findings, anchored in a bacterial strain isolated from Vietnamese soybean whey, are worth understanding on their own terms.

L. plantarum W12 produced 34.5 mM GABA in optimized soymilk

The central result in this study is a GABA yield of 34.5 mM achieved by a strain designated Lactiplantibacillus plantarum W12. That figure represents a 3.8-fold improvement over the 9.1 mM the same strain produced before optimization, making it one of the more striking yield jumps reported for a food-grade fermentation system. GABA is produced inside the bacterium through an enzyme called glutamate decarboxylase (GAD), which converts monosodium glutamate (MSG) into GABA. The researchers used Response Surface Methodology, a statistical tool for finding optimal factor combinations, to dial in the right concentrations of MSG and sucrose. The sweet spot landed at roughly 1.5% MSG and 10.9% sucrose, with fermentation running for 15 hours at 45 degrees Celsius. At that point GABA accumulation peaked; production was time-dependent and began to plateau after 15 hours.

The pH of the soymilk dropped from around 6.0 to 4.6 over 18 hours, driven by lactic acid production. That pH range matters because GAD enzyme activity is optimal between 4.5 and 5.5, meaning the bacterium's own metabolism helps maintain the conditions in which it produces GABA most efficiently. Lactic acid dominated the organic acid profile at 182.4 mg/g by 18 hours, with a lactic-to-acetic acid ratio of 165:1, confirming W12 as a homofermentative strain. That fermentation profile is considered desirable for sensory quality: mild acidity, a clean flavour, and effective antimicrobial preservation.

Soymilk as a functional food vehicle for GABA and probiotics

Soymilk is already a nutritionally attractive base: cholesterol-free, lactose-free, and rich in protein, unsaturated fatty acids, and isoflavones associated with cardiovascular and antidiabetic effects. Fermentation adds another layer. Research on fermented soymilk's bioavailability benefits has shown that the fermentation process improves mineral and vitamin accessibility, boosts isoflavone activity, and enhances antioxidant properties. Layering GABA production on top of that base, using a probiotic strain that survives gut transit, is the functional food design this study is attempting.

GABA itself has attracted food-science attention because it does not require crossing the blood-brain barrier to exert some of its physiological effects; peripheral receptors in the gut and cardiovascular system appear to mediate its blood-pressure and anxiolytic associations. Concentrating GABA in a fermented drink, rather than in a synthetic supplement, is appealing from a regulatory and consumer standpoint. Lactiplantibacillus plantarum has a long history of safe use in fermented food production and is among the most studied species for GABA biosynthesis, lending credibility to the choice of organism here.

How the team screened and optimized W12

Five L. plantarum strains were isolated from Vietnamese soybean whey and screened for GABA output and probiotic characteristics. W12 outperformed the others and was taken forward into optimization. Its probiotic credentials were assessed across several standard benchmarks: 97.1% survival at pH 2.5 (simulating stomach acid), 96.5% survival in bile salts and pancreatin (simulating the small intestine), and 97.3% tolerance to pepsin. Viable cell counts in the finished soymilk exceeded 7.9 log CFU/mL, clearing the threshold typically cited for probiotic products.

W12 also showed high auto-aggregation (96.7%) and surface hydrophobicity in chloroform (85.4%), both of which correlate with a bacterium's ability to adhere to gut epithelium and compete against pathogens. On the antimicrobial side, W12 produced inhibition zones of 28 mm against Staphylococcus aureus, 14.33 mm against Salmonella, and 3.00 mm against E. coli. These effects are primarily attributed to organic acid production and the resulting pH drop rather than to any novel antimicrobial compound. The GAD gene expression pathway in L. plantarum strains has been investigated in parallel by other research groups, and W12's results align with findings suggesting strong GABA-producing phenotypes are reproducible across well-characterized strains of this species.

What remains unvalidated before this reaches a bottle

The authors are clear about what the study does not yet answer. The GABA yield of 34.5 mM was measured in controlled laboratory fermentation; whether that concentration survives commercial storage conditions, temperature variation, and processing steps is unknown. Challenges in scaling GABA-fortified fermented foods include strain-dependent variability, storage stability, and regulatory compliance, and none of those questions are resolved by a single optimization study. Similarly, the probiotic survival figures come from simulated gastrointestinal conditions in vitro, not from human gut colonisation trials.

In vivo pharmacokinetic data on GABA bioavailability from this specific product do not yet exist. Whether the GABA that survives fermentation is absorbed and active in humans at the doses achievable through food consumption remains an open question across the field, not just for this product. The researchers call explicitly for animal model studies, molecular tracking of probiotic persistence in the gut, and sensory acceptability panels before any commercialization case can be made. A cost-effectiveness analysis for scale-up, accounting for MSG substrate costs and fermentation efficiency, is also listed as future work.

Next steps toward a commercial probiotic GABA drink

The immediate research agenda the authors sketch is logical: confirm GABA bioavailability in vivo, test shelf-life under realistic storage conditions, and run sensory panels to check whether the flavour profile is acceptable to consumers. Future research on GABA-enriched functional foods more broadly will need to address GABA stability during storage and emerging enrichment technologies that don't compromise other active ingredients, challenges that apply squarely to a fermented soymilk product.

What the study does establish, within its scope, is a reproducible optimization framework: a specific strain with quantified probiotic tolerance, a statistically validated combination of substrate concentrations, and a fermentation timeline that maximises GABA yield. For a field that often reports promising strains without robust optimization data, that combination gives this work a practical foundation to build from, even if the building is only just beginning.

Evidence rating

INVESTIGATIONAL — 61/100

Caveats:

• All findings are from in vitro laboratory experiments; no animal or human studies have been conducted.
• Whether GABA produced in this fermented beverage reaches the brain or exerts any clinical effect in humans has not been tested.
• The strain has not been evaluated for probiotic persistence or colonization in a living gut.
• Sensory acceptability, shelf-life stability, and scale-up feasibility remain unassessed.

Single in vitro characterization study of one novel bacterial strain under laboratory fermentation conditions. All findings reflect bench-scale optimization and simulated gastrointestinal assays; no animal or human subjects were involved. Results cannot establish any causal link between consumption of this product and health outcomes, and have not been replicated in independent studies.

References

1. Cao Cuong Nguyen, Bir Bahadur Thapa, Ngoc Hieu Nguyen, et al. (2026). Development of Gamma-Aminobutyric Acid (GABA)-Rich and Probiotic-Fermented Soymilk Using Lactiplantibacillus plantarum W12 as a Starter Culture. Food Technology and Biotechnology. https://doi.org/10.17113/ftb.64.02.26.9241
2. Dina Y. Abdelghani, Abdallah I. Gad, Mona M. Orabi, et al. (2022). Bioactivity of Organic Fermented Soymilk as Next-Generation Prebiotic/Probiotics Mixture. Fermentation. https://doi.org/10.3390/fermentation8100513
3. Massimo Iorizzo, Gianluca Paventi, Catello Di Martino (2023). Biosynthesis of Gamma-AminoButyric Acid (GABA) by<em> Lactiplantibacillus plantarum</em> in Fermented Food Production. https://doi.org/10.20944/preprints202311.1843.v1
4. Heba Abdel-motaal, Amro Abdelazez, Peikun Wang, et al. (2024). Exploring Phenotype, Genotype, and the Production of Promising GABA Postbiotics by Lactiplantibacillus plantarum: A Comprehensive Investigation. Fermentation. https://doi.org/10.3390/fermentation10060309
5. Muhammad Ameer Ushidee-Radzi, Chong Shin Yee, Raja Balqis Raja-Razali, et al. (2025). Advances in GABA-Enriched Yogurt and Frozen Yogurt: Microbial Biosynthesis, Functional Properties, and Health Perspectives—A Comprehensive Review. Foods. https://doi.org/10.3390/foods14244254
6. Dianzhi Hou, Jian Tang, Qiqian Feng, et al. (2023). Gamma-aminobutyric acid (GABA): a comprehensive review of dietary sources, enrichment technologies, processing effects, health benefits, and its applications. Critical Reviews in Food Science and Nutrition. https://doi.org/10.1080/10408398.2023.2204373